Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours

Summary Background Somatostatin analogues ( SSA ) represent one of the main therapeutic option in patients affected with functioning well‐differentiated neuroendocrine tumours ( NET s). There are no studies specifically focusing on NET s associated with Multiple Endocrine Neoplasia type 1 ( MEN 1). Aim To evaluate the efficacy of the long‐acting SSA octreotide in MEN 1 patients with early‐stage duodeno‐pancreatic NET s. Patients and Methods...